• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "抗血管生成" 4 results
        • 抗血管生成與腫瘤微環境關系的研究進展

          血管生成是腫瘤發展、轉移的重要條件。以往曾認為抗血管生成可抑制腫瘤生長并減少遠處轉移。最近的研究表明,抗血管生成治療不僅可產生耐藥,短期應用反而會增加腫瘤轉移復發的風險,這與腫瘤微環境的反應性變化密不可分。現就抗血管生成治療后腫瘤微環境反應性改變的研究進展作一闡述,以期對抗血管生成治療產生耐藥及增加腫瘤轉移和復發風險的機制進行更深入的探討與研究,尋找抗腫瘤治療的新靶點,從而改善抗腫瘤血管生成治療的效果。

          Release date:2016-09-07 02:38 Export PDF Favorites Scan
        • Advances of Study on Angiogenesis and Antiangiogenic Therapy in Hepatocellular Carcinoma

          Objective To introduce the possible effects and significances of angiogenesis and antiangiogenic in the development and treatment of hepatocellular carcinoma (HCC). Methods Recently relevant literatures were reviewed. Results Angiogenesis played a significant role in the development and therapy of HCC, and the development and metastasis of HCC could be effectively suppressed by antiangiogenic therapy. This might provide a new approach for the treatment of HCC. Conclusion Comprehending the molecular mechanism of angiogenesis and applying antiangiogenic therapy will contribute a lot for the prevention and treatment of HCC.

          Release date:2016-09-08 10:56 Export PDF Favorites Scan
        • 三陰乳腺癌抗血管生成治療進展及影像學評價

          三陰乳腺癌(TNBC)是乳腺癌中一個特殊的類型,具有特殊的分子表達類型和生物學特性,內分泌治療和曲妥珠單抗靶向治療無效且無明確治療靶點,復發早、進展快、生存期短、早期易發生遠處轉移等特點。此類型乳腺癌對常規放射、化學治療不敏感,導致其預后較其他類型乳腺癌差。對TNBC靶向治療的深入研究,有助于人們采取更有效的治療手段來提高療效。在實體瘤的惡性生長及轉移中,腫瘤的新生血管生成起著至關重要的作用,針對新生血管生成靶向治療的研究成為熱點。MRI技術是診斷乳腺癌的最準確的影像學方法,有助于腫瘤診斷、治療方案制定、治療反應及預后評估,并能加深對其生物學行為的理解。現對TNBC抗血管生成靶向治療進展及MRI影像學療效評價進行綜述。

          Release date: Export PDF Favorites Scan
        • Progress in medical treatment of ovarian cancer

          The mortality rate of ovarian cancer is the highest among female reproductive tract malignancies. Although most patients have undergone recurrent treatments such as surgery, chemotherapy, and targeted therapy, the recurrence rate is still high. The exploration of scholars in this field has never stopped. In recent years, remarkable achievements have been made in the medical treatment of ovarian cancer. The research of poly adenosinediphosphate-ribose polymerase, immunotherapy (immunocheckpoint inhibitor monotherapy, immune checkpoint inhibitor combined with other drugs) and anti-angiogenic drugs have provided new methods for the treatment of this disease, and throughout the whole process of ovarian cancer treatment. This paper summarizes this, and aims to provide a reference for the clinical treatment of ovarian cancer.

          Release date:2021-04-15 05:32 Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜